UY33742A - ? GPR 119 MODULATORS ?. - Google Patents
? GPR 119 MODULATORS ?.Info
- Publication number
- UY33742A UY33742A UY0001033742A UY33742A UY33742A UY 33742 A UY33742 A UY 33742A UY 0001033742 A UY0001033742 A UY 0001033742A UY 33742 A UY33742 A UY 33742A UY 33742 A UY33742 A UY 33742A
- Authority
- UY
- Uruguay
- Prior art keywords
- gpr
- modulators
- protein
- receptor coupled
- gpr119 receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En la presente se describen compuestos que modulan la actividad del receptor GPR119 acoplado a la proteína G y sus usos para el tratamiento de enfermedades relacionadas con la modulación del receptor GPR119 acoplado a la proteína G en animales.Compounds that modulate the activity of the GPR119 receptor coupled to the G protein and its uses for the treatment of diseases related to the modulation of the GPR119 receptor coupled to the G protein in animals are described herein.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41644110P | 2010-11-23 | 2010-11-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33742A true UY33742A (en) | 2012-06-29 |
Family
ID=45418722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033742A UY33742A (en) | 2010-11-23 | 2011-11-21 | ? GPR 119 MODULATORS ?. |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP2643310A1 (en) |
JP (1) | JP2013543885A (en) |
KR (1) | KR20130083915A (en) |
CN (1) | CN103298801A (en) |
AP (1) | AP2013006809A0 (en) |
AR (1) | AR088121A1 (en) |
AU (1) | AU2011333427A1 (en) |
BR (1) | BR112013011865A2 (en) |
CA (1) | CA2814231A1 (en) |
CL (1) | CL2013001054A1 (en) |
CO (1) | CO6801716A2 (en) |
CR (1) | CR20130139A (en) |
CU (1) | CU20130059A7 (en) |
DO (1) | DOP2013000102A (en) |
EA (1) | EA201370118A1 (en) |
EC (1) | ECSP13012630A (en) |
GT (1) | GT201300135A (en) |
MA (1) | MA34805B1 (en) |
MX (1) | MX2013004083A (en) |
NI (1) | NI201300044A (en) |
PE (1) | PE20140409A1 (en) |
SG (1) | SG189830A1 (en) |
TW (1) | TWI433843B (en) |
UY (1) | UY33742A (en) |
WO (1) | WO2012069948A1 (en) |
ZA (1) | ZA201302362B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6463631B2 (en) | 2011-06-09 | 2019-02-06 | ライゼン・ファーマシューティカルズ・エスアー | Novel compounds as modulators of GPR-119 |
CN104780915A (en) | 2012-07-11 | 2015-07-15 | 埃尔舍利克斯治疗公司 | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
JP2017119628A (en) * | 2014-05-09 | 2017-07-06 | 日産化学工業株式会社 | Substituted azole compound and therapeutic agent for diabetes |
CN104892517A (en) * | 2015-02-13 | 2015-09-09 | 佛山市赛维斯医药科技有限公司 | Hydrazine compound, method for preparing same and application of hydrazine compound |
CN104610151A (en) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | Compound containing hydrazide and alkoxy benzene structures as well as preparation method and application thereof |
CN104592120A (en) * | 2015-02-13 | 2015-05-06 | 佛山市赛维斯医药科技有限公司 | Cyclopropyl hydrazide and methoxybenzene-containing GPR119 agonist as well as preparation method and application thereof |
EP3416959B1 (en) | 2016-02-18 | 2021-05-12 | Syngenta Participations AG | Pesticidally active pyrazole derivatives |
CN106631992B (en) * | 2017-01-05 | 2019-01-18 | 桑迪亚医药技术(上海)有限责任公司 | A kind of synthetic method of 4- oxygen -3,4- dihydro -2H- pyridine -1- t-butyl formate |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2185544B1 (en) * | 2007-07-19 | 2014-11-26 | Cymabay Therapeutics, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 for the treatment of diabetes and metabolic disorders |
TW201002705A (en) * | 2008-03-31 | 2010-01-16 | Metabolex Inc | Oxymethylene aryl compounds and uses thereof |
NZ596467A (en) * | 2009-06-05 | 2014-01-31 | Pfizer | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
-
2011
- 2011-11-09 JP JP2013540458A patent/JP2013543885A/en active Pending
- 2011-11-09 CA CA2814231A patent/CA2814231A1/en not_active Abandoned
- 2011-11-09 MA MA35928A patent/MA34805B1/en unknown
- 2011-11-09 MX MX2013004083A patent/MX2013004083A/en unknown
- 2011-11-09 AU AU2011333427A patent/AU2011333427A1/en not_active Abandoned
- 2011-11-09 BR BR112013011865A patent/BR112013011865A2/en not_active IP Right Cessation
- 2011-11-09 SG SG2013023189A patent/SG189830A1/en unknown
- 2011-11-09 CN CN2011800550665A patent/CN103298801A/en active Pending
- 2011-11-09 AP AP2013006809A patent/AP2013006809A0/en unknown
- 2011-11-09 KR KR1020137013064A patent/KR20130083915A/en not_active Application Discontinuation
- 2011-11-09 WO PCT/IB2011/054996 patent/WO2012069948A1/en active Application Filing
- 2011-11-09 EA EA201370118A patent/EA201370118A1/en unknown
- 2011-11-09 PE PE2013001058A patent/PE20140409A1/en not_active Application Discontinuation
- 2011-11-09 EP EP11802149.2A patent/EP2643310A1/en not_active Withdrawn
- 2011-11-21 UY UY0001033742A patent/UY33742A/en unknown
- 2011-11-22 AR ARP110104351A patent/AR088121A1/en not_active Application Discontinuation
- 2011-11-22 TW TW100142804A patent/TWI433843B/en not_active IP Right Cessation
-
2013
- 2013-03-22 CR CR20130139A patent/CR20130139A/en unknown
- 2013-04-02 ZA ZA2013/02362A patent/ZA201302362B/en unknown
- 2013-04-16 CL CL2013001054A patent/CL2013001054A1/en unknown
- 2013-04-23 CU CU2013000059A patent/CU20130059A7/en unknown
- 2013-05-09 DO DO2013000102A patent/DOP2013000102A/en unknown
- 2013-05-13 NI NI201300044A patent/NI201300044A/en unknown
- 2013-05-20 EC ECSP13012630 patent/ECSP13012630A/en unknown
- 2013-05-21 GT GT201300135A patent/GT201300135A/en unknown
- 2013-05-23 CO CO13127143A patent/CO6801716A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MA34805B1 (en) | 2014-01-02 |
NI201300044A (en) | 2013-08-01 |
CA2814231A1 (en) | 2012-05-31 |
SG189830A1 (en) | 2013-06-28 |
PE20140409A1 (en) | 2014-03-23 |
AU2011333427A1 (en) | 2013-04-11 |
CR20130139A (en) | 2013-06-28 |
EP2643310A1 (en) | 2013-10-02 |
DOP2013000102A (en) | 2013-07-15 |
KR20130083915A (en) | 2013-07-23 |
CU20130059A7 (en) | 2013-06-28 |
GT201300135A (en) | 2015-02-19 |
MX2013004083A (en) | 2013-06-13 |
WO2012069948A1 (en) | 2012-05-31 |
TWI433843B (en) | 2014-04-11 |
AP2013006809A0 (en) | 2013-04-30 |
CO6801716A2 (en) | 2013-11-29 |
BR112013011865A2 (en) | 2016-08-23 |
AR088121A1 (en) | 2014-05-14 |
TW201300373A (en) | 2013-01-01 |
EA201370118A1 (en) | 2013-12-30 |
CN103298801A (en) | 2013-09-11 |
ZA201302362B (en) | 2014-06-25 |
CL2013001054A1 (en) | 2013-09-27 |
JP2013543885A (en) | 2013-12-09 |
ECSP13012630A (en) | 2013-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY32683A (en) | GPR MODULATORS 119 | |
DOP2013000102A (en) | GPR MODULATORS 119 | |
CL2015002567A1 (en) | Compounds and their uses to modulate hemoglobin | |
UY35427A (en) | COMPOUNDS AND THEIR USES IN THE MODULATION OF HEMOGLOBIN | |
UY35425A (en) | COMPOUNDS AND THEIR USES IN THE MODULATION OF HEMOGLOBIN | |
UY35426A (en) | COMPOUNDS AND THEIR USES IN THE MODULATION OF HEMOGLOBIN | |
ECSP14014544A (en) | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | |
SV2016005192A (en) | COMPOSITIONS AND METHODS TO MODULATE X-FARNESOID RECEPTORS | |
NI201400120A (en) | DIACILGLICEROL ACILTRANSFERASE 2 INHIBITORS | |
CR20150003A (en) | TIAZOLS REPLACED BY CARBOXAMIDE OR SULFONAMIDE AND RELATED DERIVATIVES AS MODULATORS FOR THE RORY NUCLEAR RECEPTOR | |
BRPI1002601E2 (en) | nanostructured composition for veterinary use for drug administration | |
EA201590881A1 (en) | THERAPEUTIC CONNECTIONS AND COMPOSITIONS AND THEIR USE AS MODULATORS PK-M2 | |
GT201300118A (en) | ESPIRO-OXINDOL MDM2 ANTAGONISTS | |
ECSP12011720A (en) | HETEROCYCLIC COMPOUNDS AND USES OF THE SAME | |
CR20110509A (en) | PHARMACEUTICAL COMPOSITION | |
UY33202A (en) | PROTEINS OF UNION TO CD127 | |
UY34773A (en) | INDANOYLOXIDIHYDROBENZOFURANILACETIC ACIDS AS MODULATORS OF THE ACTIVITY OF GPR40, COMPOSITIONS CONTAINING THEM AND THEIR USES | |
AR113543A2 (en) | OXABOROL ESTERS AND THEIR USES | |
BR112015000051A2 (en) | treatment of inflammatory skin disorders | |
UY33409A (en) | NON-COMPETITIVE MODULATORS OF NICOTINIC RECEPTORS | |
UY33662A (en) | COMBINATIONS THAT INCLUDE DHODH INHIBITORS AND COX INHIBITORS | |
BR112016030291A2 (en) | combination therapy | |
CO7151508A2 (en) | Progesterone receptor modulators for use in the prevention or treatment of androgen-mediated diseases | |
UY34479A (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES ISOMETAMIDIUM CHLORIDE IN SOLUTION FOR THE TREATMENT OF TRIPANOSOMIASIS IN ANIMALS |